https://www.live-feeds.com/feed/novartis-says-pelacarsen-heart-disease-drug-missed-primary-endpointContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-says-pelacarsen-heart-disease-drug-missed-primary-endpointhttps://www.live-feeds.com/feed/novartis-says-pelacarsen-heart-disease-drug-missed-primary-endpoint#u61486Tue, 08 Sep 2026 13:55:50 +0000Novartis shares fell after the company announced consecutive late-stage clinical trial failures for two experimental therapies. The experimental heart disease drug pelacarsen successfully lowered lipoprotein(a) levels in more than 8,000 patients but failed to reduce cardiovascular deaths, heart attacks, or strokes. Days later, the Swiss drugmaker reported a second setback when its neuromuscular disease therapy del-desiran failed a late-stage study without delivering a statistically significant improvement. These back-to-back pipeline blows also triggered drops for industry peers such as Amgen. https://www.live-feeds.com/feed/novartis-says-pelacarsen-heart-disease-drug-missed-primary-endpointhttps://www.live-feeds.com/feed/novartis-says-pelacarsen-heart-disease-drug-missed-primary-endpoint#u60478Mon, 07 Sep 2026 20:12:38 +0000Novartis shares fell more than 3% on Monday after the company announced that its experimental drug pelacarsen failed to meet the primary endpoint in the Lp(a)HORIZON trial. The late-stage study enrolled over 8,000 patients with lipoprotein(a) levels of 70mg/dL or above. Despite successfully lowering this genetic risk factor, the drug did not reduce the risk of strokes, heart attacks, or other major adverse cardiovascular events. The result raises industry concerns regarding the efficacy of therapies targeting Lp(a) to prevent heart disease.Why it mattersPelacarsen was designed to lower genetic https://www.live-feeds.com/feed/novartis-says-pelacarsen-heart-disease-drug-missed-primary-endpointhttps://www.live-feeds.com/feed/novartis-says-pelacarsen-heart-disease-drug-missed-primary-endpoint#u59325Mon, 07 Sep 2026 02:37:10 +0000Novartis announced that its experimental heart disease drug, Pelacarsen, failed to meet its primary endpoint in a late-stage clinical trial. The study focused on cholesterol and was closely watched by the medical community. Following the announcement, after-hours stock prices for Novartis, Ionis, and Amgen declined. The failure has surprised cardiologists, as the drug was considered a key experimental treatment for heart disease.Why it mattersPelacarsen was developed as a potential treatment to lower cholesterol and reduce cardiovascular risk. Its failure removes a high-profile candidate from